Eurostars – Klebsicure E!7563

Project number: E7421/15/NCBR/2013

Project duration: 01.08.2012 – 31.07.2015

Project title: „Development of monoclonal antibody-based passive immune therapy and companion diagnostics for severe Klebsiella infections”

Consortium:
Arsanis Biosciences GmbH (Vienna, Austria)- Lider
GATC GmbH (Constance, Germany)
The Max Planck Institute for Infectious Biology (Berlin, Germany)
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (Wroclaw, Poland)
Project duration: 01.08.2012 – 31.07.2015

Total cost: 4 696 700 €
Arsanis: 2 847 000 €
GATC: 1 057 200 €
MPG: 426 000 €
IITD PAN: 366 500 €

Financial support:
Eurostars Programme – joint programme between EUREKA and the European Commission, co-funded from the national budgets: Poland: The National Centre for Research and Development

Project description:
The consortium is aiming to develop a human monoclonal antibody based passive immunization against fast emerging multi-drug resistant Klebsiella infections that are associated with high lethality in hospitals. To identify patients for the therapy, quick companion diagnostics will be also developed.

Press release: “Arsanis expands its anti-infective monoclonal antibody programs with additional grant support from FFG and EUROSTARS”